DASH diet rated best overall diet for 5th year in a row
the ONA take:
The DASH (Dietary Approaches to Stop Hypertension) diet, which is rich in vegetables, whole grains, and low-fat dairy, has been named the best overall diet for the fifth year in a row by U.S. News & World Report rankings.
The DASH diet placed higher than Weight Watchers and the Mediterranean diet, which focuses on a diet rich in vegetables, fruits, fish, olive oil, and legumes.
The DASH diet was initially developed to combat hypertension without antihypertensive medications, but the diet has also been chosen by health expert as the best diet to combat diabetes and the best diet for healthy eating. Weight Watchers, however, was named again as the best diet for weight loss.
The health experts that rated the various diets say that the DASH diet is very good for weight loss and lowering blood pressure and blood sugar because it is a balanced diet. In contrast, the paleo diet, which focuses on a diet rich in meat, fish, and vegetables was ranked in last place.
The DASH diet, TLC diet, and Ornish diet were named as the top heart-healthy diets. The rankings are determined by a panel of over 20 health experts in nutrition, diet, heart disease, obesity, food psychology, and diabetes.
The DASH diet has been named the best overall diet for the fifth year in a row.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- Patients With Urologic Cancer Need Psycho-oncologic Support to Manage High Stress
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|